Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip
Corcept Therapeutics recently announced successful results from its ROSELLA trial for relacorilant plus nab-paclitaxel, indicating a notable positive stride in treatment for platinum-resistant ovarian cancer. This announcement, emphasizing a significant improvement in progression-free and overall survival, aligns with the company’s 8% share price uptick over the last quarter. Despite broader market challenges and a slide…
